M&A Reporting, CTFN

Jonathan Spitzer

M&A Reporting

CTFN

Bringing the marketplace leading coverage of mergers, events, and major corporate actions, CTFN has a team of seasoned reporters from Los Angeles to London, publishing news that advances stories that matter to event-driven investors and deal professionals.

Event-Driven

Investors are generally aware of the roles Chinese regulators such as the State Administration of Foreign Exchange and the Ministry of Commerce of the Government of the People’s Republic of China play in reviewing transactions. However, SAFE and Mofcom are less influential than the National Development and Reform Commission when it comes to effects on Chinese outbound M&amp;A, sources told CTFN.

Investors are generally aware of the roles Chinese regulators such as the State Administration of Foreign Exchange and the Ministry of Commerce of the Government of the People’s Republic of China play in reviewing transactions. However, SAFE and Mofcom are less influential than the National Development and Reform Commission when it comes to effects on Chinese outbound M&amp;A, sources told CTFN.

Investors Pay Heed to NDRC on Chinese Outbound M&A

The outcome of the planned $43 billion merger between Swiss biotech giant Syngenta and chemical conglomerate ChemChina will mainly depend on whether the parties receive US blessing for the deal, three lawyers familiar with the industry told CTFN.

The outcome of the planned $43 billion merger between Swiss biotech giant Syngenta and chemical conglomerate ChemChina will mainly depend on whether the parties receive US blessing for the deal, three lawyers familiar with the industry told CTFN.

Syngenta/ChemChina Merger Hinges on US Approval

The merger of China National Chemical Corp. and Syngenta AG, will attract close attention by CFIUS, with experts telling <a href="http://ctfn.news" target="_blank">CTFN</a> the deal could raise intellectual property issues related to the Swiss company’s involvement in the development of genetically modified organisms in the U.S.

The merger of China National Chemical Corp. and Syngenta AG, will attract close attention by CFIUS, with experts telling CTFN the deal could raise intellectual property issues related to the Swiss company’s involvement in the development of genetically modified organisms in the U.S.

Syngenta-ChemChina Review Could Focus on IP Transfer

Switzerland

Syngenta AG produces crop protection products and seeds.  The Company produces herbicides, insecticides and fungicides, and seeds for field crops, vegetables, and flowers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Syngenta AG (SYNN VX)

Investors Pay Heed to NDRC on Chinese Outbound M&A

Investors are generally aware of the roles Chinese regulators such as the State Administration of Foreign Exchange and the Ministry of Commerce of...

CTFN

Syngenta/ChemChina Merger Hinges on US Approval

The outcome of the planned $43 billion merger between Swiss biotech giant Syngenta and chemical conglomerate ChemChina will mainly depend on...

CTFN

Syngenta-ChemChina Review Could Focus on IP Transfer

The merger of China National Chemical Corp. and Syngenta AG, will attract close attention by CFIUS, with experts telling CTFN the deal could raise...

CTFN

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)